STOCK TITAN
  1. Home
  2. Sec-filings
  3. GDRX
  4. [8-K] GoodRx Holdings, Inc. Reports Material Event

GoodRx (GDRX) Board approves $72,918 bonus for Chief Accounting Officer

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

GoodRx Holdings, Inc. reported a new executive compensation decision. On March 3, 2026, the Board of Directors, following a recommendation from its Compensation Committee, approved a discretionary cash bonus of $72,918 to Chief Accounting Officer Romin Nabiey for his performance during 2025.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001809519FALSE2701 Olympic BoulevardSanta MonicaCalifornia00018095192026-03-032026-03-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________
FORM 8-K
________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 3, 2026
________________________________________
GoodRx Holdings, Inc.
(Exact Name of Registrant as Specified in its Charter)
________________________________________
Delaware
001-39549
47-5104396
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
2701 Olympic Boulevard
Santa Monica, California
90404
(Address of Principal Executive
Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (855) 268-2822
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per
share
GDRX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Compensatory Arrangements of Certain Executive Officers
On March 3, 2026, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the
recommendation of the Compensation Committee of the Board approved a discretionary cash bonus for 2025 performance
in the amount of $72,918 for Romin Nabiey, the Company’s Chief Accounting Officer.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
GOODRX HOLDINGS, INC.
Date:
March 6, 2026
By:
/s/ Christopher McGinnis
Name: Christopher McGinnis
Title: Chief Financial Officer & Treasurer

Source: View Original Filing on SEC EDGAR

FAQ

What executive compensation change did GoodRx (GDRX) disclose?

GoodRx disclosed a discretionary cash bonus of $72,918 for its Chief Accounting Officer, Romin Nabiey. The payment recognizes his performance during 2025 and was formally approved by the company’s Board of Directors after a recommendation from the Compensation Committee.

Who is receiving the discretionary bonus at GoodRx (GDRX)?

The discretionary cash bonus is being awarded to Romin Nabiey, GoodRx’s Chief Accounting Officer. The Board of Directors approved the payment following a recommendation from the Compensation Committee, specifically recognizing his performance for the company during the 2025 fiscal year.

How much is the discretionary cash bonus GoodRx (GDRX) approved?

GoodRx approved a discretionary cash bonus of $72,918 for its Chief Accounting Officer. This amount reflects the Board’s assessment of his 2025 performance, based on the Compensation Committee’s recommendation, and represents a one-time cash award rather than equity compensation.

When did GoodRx (GDRX) approve the 2025 performance bonus?

GoodRx’s Board of Directors approved the discretionary 2025 performance bonus on March 3, 2026. The decision followed a recommendation from the Board’s Compensation Committee and resulted in a cash award of $72,918 to Chief Accounting Officer Romin Nabiey.

Which GoodRx (GDRX) board body recommended the bonus to the CAO?

The Compensation Committee of GoodRx’s Board of Directors recommended the discretionary cash bonus. Acting on this recommendation, the full Board approved a $72,918 payment to Chief Accounting Officer Romin Nabiey in recognition of his performance for the company during 2025.

Filing Exhibits & Attachments

3 documents

Other Documents